We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

233 hedge funds and large institutions have $2.09B invested in BioCryst Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 67 increasing their positions, 71 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more call options, than puts

Call options by funds: $92M | Put options by funds: $34.8M

138% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 21

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

29% more capital invested

Capital invested by funds: $1.62B → $2.09B (+$470M)

13% more funds holding

Funds holding: 206 → 233 (+27)

3.21% more ownership

Funds ownership: 66.01% → 69.22% (+3.2%)

6% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 71

Holders
233
Holders Change
+27
Holders Change %
+13.11%
% of All Funds
3.68%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
50
Increased
67
Reduced
71
Closed
21
Calls
$92M
Puts
$34.8M
Net Calls
+$57.2M
Net Calls Change
+$18M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$72.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$60.9M
3
Victory Capital Management
Victory Capital Management
Texas
+$49.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$37.2M
5
ACA
Avoro Capital Advisors
New York
+$30.1M

Top Sellers

Rank Fund Capital Flow
1
SCM
Sarissa Capital Management
Connecticut
-$42.5M
2
HM
HealthCor Management
New York
-$34.5M
3
SI
Sofinnova Investments
California
-$20.9M
4
Two Sigma Investments
Two Sigma Investments
New York
-$16.4M
5
BCPEMI
Bain Capital Public Equity Management II
Massachusetts
-$14.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
KM
151
Kalos Management
Georgia
$381K -$30.6K -1,909 -8%
AB
152
Amalgamated Bank
New York
$375K -$15.7K -977 -4%
AF
153
Amalgamated Financial
New York
$375K +$370K +23,092 New
QIM
154
Quantitative Investment Management
Virginia
$342K +$337K +21,035 New
VF
155
Virtu Financial
New York
$336K +$331K +20,645 New
BC
156
Birchview Capital
Vermont
$325K – – –
CB
157
Commerce Bank
Missouri
$325K – – –
CWS
158
Cypress Wealth Services
California
$325K – – –
Walleye Trading
159
Walleye Trading
New York
$314K -$279K -17,390 -47%
DT
160
Diversified Trust
Tennessee
$296K – – –
CA
161
Cetera Advisors
Colorado
$295K +$291K +18,155 New
DTL
162
Dynamic Technology Lab
Singapore
$293K +$289K +18,017 New
Mackenzie Financial
163
Mackenzie Financial
Ontario, Canada
$290K +$286K +17,806 New
EFM
164
E Fund Management
China
$271K +$28.2K +1,756 +12%
TRCT
165
Tower Research Capital (TRC)
New York
$263K -$139K -8,649 -35%
AWM
166
Altium Wealth Management
New York
$260K – – –
PM
167
Parametrica Management
Hong Kong
$260K +$257K +16,005 New
Verition Fund Management
168
Verition Fund Management
Connecticut
$252K +$249K +15,513 New
GAM
169
Gotham Asset Management
New York
$237K +$52K +3,240 +29%
CIBC World Market
170
CIBC World Market
Ontario, Canada
$236K – – –
Prudential Financial
171
Prudential Financial
New Jersey
$228K +$3.29K +205 +1%
AIP
172
Ameritas Investment Partners
Nebraska
$227K – – –
RCAG
173
Rehmann Capital Advisory Group
Michigan
$197K – – –
US Bancorp
174
US Bancorp
Minnesota
$197K +$8.02K +500 +4%
NA
175
NewEdge Advisors
Louisiana
$187K -$18K -1,123 -9%
5 6
7
8 9

BCRX Hedge Fund Activity: Q1 2022 in Review

233 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2022, worth a combined $2.09B — up 29% from $1.62B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new BCRX positions and 21 closed out — a net gain of 29 holders — while 67 added to existing stakes and 71 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $72.5M. The largest seller was Sarissa Capital Management, cutting an estimated $42.5M.

  • 233 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2022, up from 206 in Q4 2021.
  • Funds reported $2.09B of BioCryst Pharmaceuticals stock for Q1 2022, up 29% quarter-over-quarter.
  • 50 funds opened new BioCryst Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +29 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2022 was Fidelity Investments, an estimated $72.5M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2022 was Sarissa Capital Management, an estimated $42.5M sold.

Based on aggregated 13F filings for Q1 2022.